Authors
Latest:
The Design Behind the Development of a Novel-Risk Prediction Model in Lung Cancer ScreeningJoshua Roth, PhD, assistant member, Fred Hutchinson Cancer Research Center, discusses the design of a novel risk-prediction algorithm in the context of screening patients for lung cancer.
Latest:
Exciting NSCLC Data Updates from ESMO 2022The panel shares the data that excited them the most from ESMO 2022, and what to look forward to in the future.
Latest:
Dr. O'Shaughnessy on Key Results From the EMERALD Trial in HR+/HER2- Breast CancerJoyce A. O’Shaughnessy, MD, discusses key results from the phase 3 EMERALD trial of elacestrant, and the potential effects of the agent’s approval on the use of oral selective estrogen receptor degraders for hormone receptor–positive, HER2-negative breast cancer.
Latest:
Unmet Needs and Future Direction in HER2+ Breast CancerThe panel looks to the future landscape for HER2+ breast cancer, highlighting emerging treatment practices and currently unmet needs.
Latest:
Dr Liu on the Rationale for Targeting Wee1 in Ovarian CancerJoyce F. Liu, MD, MPH, discusses the role of Wee1 in cell cycle regulation and the rationale for targeting this protein in ovarian cancer.
Latest:
Dr. O'Shaughnessy on the Rationale for the MonarchE Trial in Breast CancerJoyce A. O'Shaughnessy, MD, discusses the rationale for the monarchE trial in breast cancer.
Latest:
Epigenetic Studies May Unlock Clues to Gene MutationsResearchers at Roswell Park Cancer Institute are formalizing their epigenetics program across dozens of disease research groups, with the goal of understanding what changes in the epigenome lead to cancer and identifying targeted, personalized ways to address these changes.
Latest:
Preoperative Monitoring and Surgical Options for HER2+ PatientsKandace P. McGuire, MD, provides clinical insights on how patient monitoring practices inform discussions around surgical options, providing the potential for deescalating surgical management.
Latest:
The Importance of Correct Coding in Specialty-Focused Cancer Treatment CentersWhen you consider how complex the system is, and how little training physicians get in medical school about coding, it stands to reason that practice leadership must emphasize its importance.
Latest:
Dr. Yang on NASH-Associated HCC and Cirrhosis in Diagnosis of Liver CancerJu Dong Yang, MD, MSc, discusses patients with nonalcoholic steatohepatitis (NASH)-associated hepatocellular carcinoma (HCC) who present without cirrhosis at the time of diagnosis of liver cancer.
Latest:
Dr. Reyna on LUGPA Member Ancillary ServicesJuan A. Reyna, MD, President, LUGPA, discusses in-office ancillary services among LUGPA members.
Latest:
Dr. O'Connor Discusses Rationale for CORRELATE Trial in mCRCJuan Manuel O’Connor, MD, head, Department Gastrointestinal Oncology, Department of Clinical Oncology, Institute Alexander Fleming, Buenos Aires, discusses the rationale for the CORRELATE trial in metastatic colorectal cancer.
Latest:
Dr. Alderuccio on the Use of Proteasome Inhibitors in Frontline MyelomaJuan P. Alderuccio, MD, assistant professor of clinical medicine at Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses the use of proteasome inhibitors in the frontline treatment of patients with multiple myeloma.
